Alvotech (ALVO) Non-Current Deffered Revenue (2021 - 2025)
Alvotech's (ALVO) quarterly Non-Current Deffered Revenue came in at $5.5 million in Q4 2025, down 93.19% YoY from $80.7 million in Q4 2024, and down 57.41% on a QoQ basis from $12.9 million in Q2 2025.
Alvotech (ALVO) Non-Current Deffered Revenue (2021 - 2025) Analysis & Trends
Alvotech (ALVO) has 5 years of Non-Current Deffered Revenue data on file, last reported at $5.5 million in Q4 2025.
- Quarterly Non-Current Deffered Revenue fell 93.19% year-over-year to $5.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.5 million (down 93.19% YoY) and the FY2025 annual result came in at $5.5 million, down 93.19% from the prior year.
- Non-Current Deffered Revenue eased to $5.5 million in Q4 2025, from $12.9 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $90.1 million in Q2 2024 to a low of $5.5 million in Q4 2025.
- A 5-year average of $52.7 million and a median of $57.2 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue jumped 57.0% — and 2025, when it plunged 93.19%.
- Tracing ALVO's Non-Current Deffered Revenue over 5 years: stood at $44.8 million in 2021, then grew by 27.15% to $57.0 million in 2022, then gained by 28.49% to $73.3 million in 2023, then rose by 10.18% to $80.7 million in 2024, then sank by 93.19% to $5.5 million in 2025.
- The last three Non-Current Deffered Revenue figures came in at $5.5 million (Q4 2025), $12.9 million (Q2 2025), and $80.7 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alvotech | 1.26 Bn | 1.26 Bn | 5.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.50 Mn |
| Jun 30, 2025 | 12.91 Mn |
| Dec 31, 2024 | 80.72 Mn |
| Jun 30, 2024 | 90.12 Mn |
| Dec 31, 2023 | 73.26 Mn |
| Jun 30, 2023 | 57.40 Mn |
| Dec 31, 2022 | 57.02 Mn |
| Dec 31, 2021 | 44.84 Mn |